Márquez HK, Rojas VA, Camacho MG

Language: Spanish
References: 11
Page: 107-115
PDF size: 284.55 Kb.

ABSTRACT

The widespread use of carbapenemics for the treatment of Klebsiella spp. infections has resulted in the appearance of carbapenemase-producing strains, which has resulted in increased mortality due to enterobacterial infection. The carbapenemase resistance pattern ranges from 24 to 70%, depending on the revised series. Carbapenemase-producing bacteria often have plasmidic genes that confer resistance to sulfonamides and aminoglycosides, as well as a high level of resistance to quinolones mediated by alteration at the binding site, which makes them multidrug-resistant bacteria, making it difficult to treat. The problem of antibiotic resistance to carbapenems is worrying, considering that we do not have a large therapeutic arsenal, which is why it has been necessary to reuse antibiotics that had previously been out of the market such as colistin, use pharmacodynamic properties of the carbapenems and to use them in high doses and extended infusions and to use therapies combined with tigecycline, fosfomycin, quinolones or aminoglycosides; thus exposing patients to great toxicity. Most reports of carbapenemase-producing entorobacteria are from adult infections. In this work, antibiotic resistance of enterobacterial infections in children, is described.

REFERENCES

1. Logan LK. Carbapenem-resistant Enterobacteriaceae: an emerging problem in children. Clin Infect Dis. 2012; 55 (6): 852-859.

2. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012; 25 (4): 682-707.

3. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. December 2013, pp 1-40.

4. Esparza G, Ariza B, Bedoya AM, Bustos I, Castañeda-Ramírez CR, De la Cadena E et al. Estrategias para la implementación y reporte de los puntos de corte CLSI vigentes y pruebas fenotípicas confirmatorias para BLEE y carbapenemasas en bacilos Gram negativos en laboratorios clínicos de Colombia. Infectio. 2013; 17 (2): 80-89.

5. Falagas ME, Rafailidis PI, Kofteridis D, Virtzili S, Chelvatzoglou FC, Papaioannou V et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother. 2007; 60 (5): 1124-1130.

6. Correa L, Martino MD, Siqueira I, Pasternak J, Gales AC, Silva CV et al. A hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection. BMC Infect Dis. 2013; 13: 80.

7. Echeverri-Toro LM, Rueda ZV, Maya W, Agudelo Y, Ospina S. Klebsiella pneumoniae multi-resistente, factores predisponentes y mortalidad asociada en un hospital universitario en Colombia. Rev Chil Infectol. 2012; 29 (2): 175-182.

8. Hsu AJ, Tamma PD. Treatment of multidrug-resistant Gram-negative infections in children. Clin Infect Dis. 2014; 58 (10): 1439-1448.

9. Rodríguez-Baño J, Cisneros JM, Cobos-Trigueros N, Fresco G, Navarro-San Francisco C, Gudiol C et al. Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology. Enferm Infecc Microbiol Clin. 2015; 33 (5): 337.e1-337.e21.

10. Fraimow H, Nahra R. Resistant gram-negative infections. Crit Care Clin. 2013; 29 (4): 895-921.

11. van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013; 75 (2): 115-120.